ELISA News and Research

RSS

Is placental antibody transfer after COVID-19 vaccination different from that after SARS-CoV-2 infection in pregnant individuals?

Researchers investigated the placental transfer ratios of anti-SARS-CoV-2 antibodies in pregnant females.

11 Nov 2022

Mosaic nanoparticles displaying spike protein trimers from different coronaviruses elicits cross-reactive protection

In a recent study under review at the Nature Portfolio journal and currently posted to Research Square* preprint server, researchers developed and assessed the immunogenicity of nanoparticles expressing spike trimers from coronaviruses (CoVs).

10 Nov 2022

Immunological responses against monkeypox virus concerning the 2022 outbreak

A new study aimed to analyze the kinetics of the pox-specific T-cell induction, the inflammatory profile, and the inflammatory profile in human cases of the current monkeypox outbreak.

9 Nov 2022

Researchers propose a deep antibody-antigen interaction algorithm to accelerate the identification of potential therapeutic antibodies

Researchers used a deep antibody-antigen interaction (DeepAAI) algorithm to understand the antibody representations of unseen antibodies to accelerate the discovery of novel antibodies with potential therapeutic applications.

9 Nov 2022

SARS-CoV-2 activates NLRP3 inflammasome

Researchers assessed the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation.

7 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

What is the correlation between specific COVID-19 clinical characteristics and anti-SARS-CoV-2 antibody titers?

Researchers investigated the associations between clinical characteristics of coronavirus disease 2019 (COVID-19) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

3 Nov 2022

Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

Researchers in the United States identified a broadly neutralizing antibody (S728-1157 bnAb) that targets the receptor-binding site (RBS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Nov 2022

New approach increases the likelihood of detecting antiphospholipid syndrome

The Geneva University Hospitals, the University of Geneva and their spin-off Endotelix have created the best possible target molecule for the antibodies responsible for antiphospholipid syndrome.

1 Nov 2022

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer.

31 Oct 2022

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The findings of a new study showed that the intranasal SpyCage vaccine platform can be protective against SARS-CoV-2 and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens.

31 Oct 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Low-density granulocytes are phenotypically altered in people with long-COVID

In a recent study posted to the bioRxiv* preprint server, researchers characterized low-density granulocyte (LDG) neutrophil (NP) proportion among individuals up to 14 months post-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection.

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Researchers reported three human monoclonal antibodies generated from COVID-19-recovered individuals during the initial wave of the pandemic in India.

27 Oct 2022

ELISA News and Research

Is placental antibody transfer after COVID-19 vaccination different from that after SARS-CoV-2 infection in pregnant individuals?

Mosaic nanoparticles displaying spike protein trimers from different coronaviruses elicits cross-reactive protection

Immunological responses against monkeypox virus concerning the 2022 outbreak

Researchers propose a deep antibody-antigen interaction algorithm to accelerate the identification of potential therapeutic antibodies

SARS-CoV-2 activates NLRP3 inflammasome

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

What is the correlation between specific COVID-19 clinical characteristics and anti-SARS-CoV-2 antibody titers?

Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

New approach increases the likelihood of detecting antiphospholipid syndrome

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Low-density granulocytes are phenotypically altered in people with long-COVID

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

What is the efficacy of mulberry component Kuwanon C against COVID-19?

Breakthrough infection risk and immune responses to vaccines associated with human leukocyte antigen alleles

SARS-CoV-2 transmission from infected owner to pet rats

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News